Conflicts Of Interest In Clinical Trial: 

References Clinical Trial 30^th December 2020. Efficacy and Safety of the mRNA Sars Cov-2 Vaccine.  Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19.

The Conflict Of Interest Statement Kicks In: However the researchers then stated serious adverse events were rare as to the conclusion of their study. However it is important to note that there was a conflict of interest statement the researched study was funded by the NHI to conduct clinical trials in collaboration with Janssen and Moderna. Receiving grant support from Pfizer, Merck, Pasteur, Eli Lilly. Consulting fees were funded by Horizon Pharma and GSK for fees on data monitoring,. Dr Bennet who was involved in the study owning stock and stock options in Moderna, Dr, Pajor another person involved in research owing stocked and being employed by Moderna, other doctors working in the research study too owned stock in Moderna and employed by Moderna.

Research finds COVID-19 Spike Protein binds to cells in the heart and couls help explain some effects of severe infection (28/08/2021). The Spike Protein found on the surface of COVID 19 virus cells causes damage to cells in the small blood vessels of the heart, according to early findings presented at the European Society of Cardiology Congress.

Researchers from the University of Bristol have found that, in cells in a dish in the lab, the spike protein binds to cells called pericytes which line the small vessels of the heart. This binding triggers a cascade of changes which disrupt normal cell function, and can lead to the release of chemicals that cause inflammation. This happened even when the protein was no longer attached to the virus. There is some previous evidence to suggest that following Covid-19 illness, the spike protein can remain in the bloodstream after the virus has gone and travel far from the site of infection. This research could help explain and ultimately treat some of the effects of severe Covid-19 infection, where levels of the virus are particularly high.

Research has shown that vaccination is a safe and effective way of reducing your risk of severe Covid infection, so is the best thing you can do to reduce your risk of Covid-19 complications, including heart damage. Researchers took small vessel cells from the heart and exposed them to the spike protein. They found that the spike protein alone was enough to disrupt normal cell function, and lead to the release of chemicals that cause inflammation.

They then blocked the CD147 receptor and found that this prevented the spike protein from causing some of the changes to the cells. However, the inflammation continued. Now the researchers hope to find out if a drug blocking CD147 in humans can help to protect people from some of the complications arising from Covid-19. Professor James Leiper, Associate Medical Director at British Heart Foundation, which funded the research, said: “Covid-19 has presented an unprecedented challenge for the cardiovascular research community. There is still a lot that is unknown relating to how the virus can impact our health in the long term

PLEASE  CLICK ON THE LINK PROVIDED WITHIN THE IMAGE ABOVE TO VIEW MY RUMBLE VIDEO ‘ NZ GOVERNMENT WAS PUT ON NOTICE ‘HOMICIDE’ AND IGNORES THE CRIMES ACT 158′

https://pubmed.ncbi.nlm.nih.gov/33378609/

https://www.bhf.org.uk/what-we-do/news-from-the-bhf/news-archive/2021/august/covid-19-spike-protein-binds-to-and-changes-cells-in-the-heart